Johnson & Johnson Covid-19 vaccine produces a strong response against the Delta variant of the virus, the company has said.
A study of blood samples taken from eight inoculated people showed that the vaccine elicits neutralizing antibody activity over the course of at least eight months against all variants, including Delta, which was first detected in India. “Today’s newly announced studies reinforce the ability of the Johnson & Johnson Covid-19 vaccine to help protect the health of people globally," said Paul Stoffels, the MD and vice chairman of the executive committee and chief scientific officer at J&J. "This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants